

**Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults:
potential for limiting the death toll during and beyond the COVID-19 pandemic**

Hermann Brenner, MD^{1,2,3,4} Bernd Holleczek, PhD^{1,5} Ben Schöttker, PhD^{1,4}

¹Division of Clinical Epidemiology and Aging Research, Germany Cancer Research Center (DKFZ), Heidelberg, Germany

²Division of Preventive Oncology, Germany Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

³German Cancer Consortium (DKTK), Germany Cancer Research Center (DKFZ), Heidelberg, Germany

⁴Network Aging Research, University of Heidelberg, Heidelberg, Germany

⁵Saarland Cancer Registry, Saarbrücken, Germany

Corresponding Author

Ben Schöttker, PhD, MPH, MSc

Division of Clinical Epidemiology and Ageing Research

German Cancer Research Center

Im Neuenheimer Feld 581

69120 Heidelberg

Germany

Phone: +49-6221-421351

Fax : +49-6221-421302

Email: b.schoettker@dkfz.de

1 **Abstract**

2 **Background.** The COVID-19 pandemic goes along with increased mortality from
3 acute respiratory disease, and measures to limit the spread of the infection go along with
4 increased risk of vitamin D deficiency, especially among high risk groups. It has been
5 suggested that vitamin D₃ supplementation might help to reduce respiratory disease
6 mortality.

7 **Methods.** We assessed the prevalence of vitamin D insufficiency and deficiency,
8 defined by 25(OH)D blood levels of 30-50 and <30 nmol/L, respectively, and their
9 association with mortality from respiratory diseases during 15 years of follow-up in a cohort
10 of 9,548 adults aged 50-75 years from Saarland, Germany.

11 **Results.** Vitamin D insufficiency and deficiency were common (44% and 15%, respectively).
12 Compared to sufficient vitamin D status, respiratory disease mortality was 2.1 (95%-CI 1.3-
13 3.2)- and 3.0 (95%-CI 1.8-5.2)-fold increased, respectively. Although significant increases
14 were seen in both women and men, they were much stronger among women, with 8.5 (95%
15 CI 2.4-30.1) and 2.3 (95% CI 1.1-4.4)-fold increase of respiratory disease mortality in case of
16 vitamin D deficiency among women and men, respectively (p-value for interaction =0.041).
17 Overall, 41% (95% CI 20%-58%) of respiratory disease mortality was statistically attributable
18 to vitamin D insufficiency or deficiency.

19 **Conclusion.** Vitamin D insufficiency and deficiency are common and account for a
20 large proportion of respiratory disease mortality in older adults, supporting suggestions that
21 vitamin D₃ supplementation might make a major contribution to limit the burden of the
22 COVID-19 pandemic, particularly among women.

23

24

25 **Introduction**

26 The Corona Virus Disease 2019 (COVID-19) pandemic goes along with strongly increased
27 respiratory disease mortality. It has been suggested that vitamin D₃ supplementation could
28 be a potentially promising and safe approach to reduce risk of COVID-19 infections and
29 deaths (1). Meta-analyses of randomized clinical trials (RCTs) have shown that vitamin D₃
30 supplementation reduces the risk of acute respiratory tract infections (2). Risk reduction with
31 regular (daily or weekly) supplementation of physiological doses of vitamin D was especially
32 strong (by 70%) among people with vitamin D deficiency, but significant risk reduction (by
33 25%) was also found among people with higher vitamin D levels.

34 People with pre-existing major diseases, such as diabetes or cancer are at increased risk of
35 dying from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. At the
36 same time, prevention of and care for these diseases have been and keep being strongly
37 compromised by current measures to limit the COVID-19 pandemic. Meta-analyses of clinical
38 trials have demonstrated that vitamin D₃ supplementation has the potential to also reduce
39 cancer mortality by approximately 13% (3).

40 We previously assessed the prevalence of vitamin D insufficiency and deficiency and their
41 association with all-cause mortality and mortality from cardiovascular, cancer and respiratory
42 diseases in a cohort of 9,548 adults aged 50-75 years from Saarland, Germany (4-8). We
43 aim to present considerably updated and sex-specific follow-up data of 15 years here and to
44 calculate the proportion of respiratory disease mortality that is attributable to vitamin D
45 insufficiency and deficiency. Furthermore, we discuss potential implications for prevention in
46 the context of the ongoing COVID-19 pandemic.

47

48

49

50 **Methods**

51 *Study design*

52 This investigation is based on the ESTHER study, an ongoing statewide cohort study from
53 Saarland, Germany, details of which have been reported elsewhere (4-9). Briefly, 9,940 men
54 and women, aged 50-75 years at baseline, were recruited by their general practitioners
55 during a routine health check-up between 2000 and 2002. Blood samples were taken at
56 baseline at the general practitioners' offices. Information on socio-demographic and lifestyle
57 characteristics and medical history were obtained by questionnaires from participants and
58 their general practitioners, and the distribution of those characteristics was similar to the
59 distribution in the respective age categories in the German National Health Survey
60 conducted in a representative sample of the German population in 1998 (9). The ESTHER
61 study was approved by the ethics committees of the University of Heidelberg and the state
62 medical board of Saarland, Germany. Written informed consent was issued by all
63 participants.

64

65 *Variable assessment*

66 Information on socio-demographic characteristics, lifestyle and diet were obtained by a
67 comprehensive self-administered questionnaire from the study participants at baseline.
68 Height and weight were assessed and documented on a standardized form by the general
69 practitioners during the health check-up. Furthermore, blood and urine samples were taken
70 during the health check-up, centrifuged, sent to the study center and stored at -80°C until
71 analysis.

72 The most abundant and stable vitamin D metabolite in blood samples, 25-hydroxyvitamin D
73 (25(OH)D) levels was measured from stored serum samples taken at recruitment. The
74 laboratory methods used are described in detail elsewhere (4). In brief, 25(OH)D levels in
75 women were measured with the Diasorin-Liaison analyzer (Diasorin Inc., Stillwater, USA).
76 Analyses in men were conducted in the context of a separate research project several years

77 later (when the Diasorin measurements were no longer offered) with IDS-iSYS
78 (Immunodiagnostic Systems GmbH, Frankfurt Main, Germany). Both immunoassays were
79 standardized retrospectively to the gold standard method liquid chromatography tandem-
80 mass-spectrometry.

81 Deaths until end of 2016 were identified by inquiry at the residents' registration offices and
82 death certificates of deceased study participants were provided by local health authorities.
83 The leading cause of death with an ICD-10 code was available for 98.9% of deceased study
84 participants and was coded with ICD-10 codes R98-R99 "unknown cause of death" for 4.4%
85 of deceased participants. These individuals were not excluded and censored at the time of
86 death for cause specific mortality outcomes.

87

88 *Statistical methods*

89 Participants of the ESTHER baseline examination (n = 9,940) were excluded from this
90 investigation if no blood sample was available (n = 368) or if they could not be followed-up for
91 mortality (n = 24), which resulted in a total sample size of n = 9,548 subjects for this analysis.

92 We used the US-American Institute of Medicine's cut-offs to define adequate vitamin D
93 status (> 50 nmol/L), vitamin D insufficiency (30-50 nmol/L) and vitamin D deficiency (< 30
94 nmol/L) (10). We assessed prevalences of vitamin D insufficiency and deficiency in the total
95 study population and according to age, sex, life-style factors and major diseases and tested
96 for differences between groups by χ^2 -test.

97 We compared all-cause, cardiovascular disease, cancer, and respiratory disease mortality
98 between subjects with vitamin D insufficiency or deficiency and subjects with adequate
99 25(OH)D levels and estimated hazard ratios (HR) with 95% confidence intervals (95%CI) by
100 multivariable Cox proportional hazards models. We used an age, sex and season adjusted
101 model and a full model that was adjusted for potential confounders, which are listed in **Table**
102 **1**. Additional adjustment for potential intermediates (cardiovascular disease, history of

103 cancer, diabetes mellitus, hypertension, asthma, total serum cholesterol and serum c-
104 reactive protein levels) did not lead to substantially different results (data not shown). Age
105 and BMI were modelled as continuous variables and all other variables were modelled with
106 the categories shown in **Table 1**. Furthermore, sex-specific analyses were performed and
107 statistical tests on interaction were carried out. In addition, we estimated the population
108 attributable fraction (PAF) of respiratory disease mortality from the prevalences of vitamin D
109 insufficiency and deficiency and their associations with respiratory disease mortality, as
110 derived from our study. The PAF of mortality is the share of mortality in a population that is
111 statistically attributable to a risk factor and that could be avoided by entirely eliminating that
112 risk factor (here: vitamin D insufficiency or deficiency) (11).

113 Missing values for covariates ranged from 0% to 5.8% (for fish consumption). Missing
114 covariate values were imputed with multiple imputation using the Markov Chain Monte Carlo
115 (MCMC) method with 200 burn-in iterations. Twenty data sets were generated. The
116 imputation model consisted of all variables of the full model (modelled as used in the full
117 model) but not the outcome data and the imputation was carried out stratified by sex.

118 All statistical tests were two-sided and the alpha level of significance was set to 0.05. All
119 statistical analyses were conducted with the software package SAS, version 9.4 (Cary, North
120 Carolina, USA).

121

122

123

Results

124 The study population included 43.8% men, mean age was 62.1 years (**Table 1**). Among the
125 9,548 participants included in the study, 4186 (43.8%) had vitamin D insufficiency (25(OH)D
126 levels of 30 - <50 nmol/L) and 1438 (15.1%) had vitamin D deficiency (25(OH)D levels <30
127 nmol/L) (**Figure 1A**). **Table 1** also provides a description of further characteristics of the
128 study population at baseline as well as prevalences of vitamin D insufficiency and deficiency
129 according to those characteristics. Both vitamin D insufficiency and deficiency were
130 statistically significantly more frequent among females, with higher age, BMI, in subjects with
131 low physical activity and those who consumed fish less than once per week. A seasonal
132 variation with higher prevalences in winter than in summer months was also observed.
133 Moreover, the prevalence of vitamin D deficiency was significantly higher among current
134 smokers.

135 Overall, 2,363 (24.7%) study participants died during a median of 15.3 years of follow-up and
136 both vitamin D insufficiency and deficiency were associated with significantly increased all-
137 cause mortality compared to sufficient vitamin D status (full model HRs [95%CI]: 1.2 [1.1-1.3]
138 and 1.7 [1.5-1.9], respectively) (**Table 2**). Vitamin D deficiency was also associated with
139 significant increases in CVD and cancer mortality by 52% and 38%, respectively (full model
140 results). However, vitamin D insufficiency and deficiency were particularly strongly
141 associated with respiratory disease mortality with full model HRs of 2.1 (95%CI: 1.3-3.2) and
142 3.0 (95%CI: 1.8-5.2), respectively. Overall, 41% (95%CI: 20%-58%) of all deaths from
143 respiratory diseases were statistically attributable to 25(OH)D levels < 50 nmol/L (**Figure**
144 **1B**).

145 **Table 3** shows the results of the sex-specific analyses. For all-cause, cardiovascular disease
146 and cancer mortality, only modest, statistically non-significant differences were seen between
147 women and men. Although significant increases were seen for respiratory disease mortality
148 in both women and men, they were much stronger among women, with 8.5 (95% CI 2.4-

149 30.1) and 2.3 (95% CI 1.1-4.4)-fold increase of respiratory disease mortality in case of
150 vitamin D deficiency among women and men, respectively (p -value for interaction =0.024).

151

152

Discussion

153 In this large population-based cohort study from Saarland, Germany, the majority of
154 participants aged 50-75 years at baseline had vitamin D insufficiency or deficiency, and
155 these conditions were associated with increased mortality. In particular, mortality from
156 respiratory diseases was 2.1- and 3.0-fold increased in subjects with vitamin D insufficiency
157 or deficiency, respectively, compared to participants with sufficient vitamin D status.
158 Significant associations with respiratory disease mortality were seen among both women and
159 men, but they were particularly strong for women. Overall, 41% of deaths from respiratory
160 diseases were statistically attributable to vitamin D insufficiency or deficiency, and could
161 possibly be avoided by overcoming these conditions assuming causality of the association.

162 The assumption of causality of vitamin D₃ effects on mortality obviously requires most careful
163 discussion. Although we made the best attempts to adjust potential confounding factors in
164 our analyses, the major limitation of our study is that we cannot exclude the possibility of
165 residual confounding by imperfect measurement of confounding variables, such as smoking
166 or physical activity, or omission of unknown confounders in this observational study. As
167 addressed in detail elsewhere (6), interpretation of the evidence is further complicated by the
168 fact that vitamin D deficiency could be considered both a consequence of poor health as well
169 as a risk factor for increased vulnerability to acute disease and poor outcomes of chronic
170 diseases among people with poor health. It is therefore paramount to critically evaluate our
171 findings in the light of additional criteria and evidence, such as biological mechanisms and
172 plausibility, and, in particular, in the light of data from RCTs providing vitamin D₃
173 supplementation.

174 Deaths from respiratory disease are mostly deaths from exacerbations of COPD which are
175 caused by acute infections in the majority of cases or from acute respiratory infections
176 causing pneumonia. Vitamin D₃ is thought to protect from occurrence and poor outcomes of
177 respiratory infections by several mechanisms, including enhanced physical barriers
178 (maintenance of junction integrity), cellular innate immunity, and adaptive immunity (1).

179 Innate and adaptive immunity are being influenced by sex hormones (12), which may explain
180 the observed interaction of sex and 25(OH)D levels with respiratory disease mortality.
181 According to data from the US-American National Health and Nutrition Survey women have a
182 higher inflammation burden than men (the age-range was 40-90+ years (13)). Especially
183 postmenopausal women, like those included in the ESTHER study, have a high inflammatory
184 burden because a decline in estrogen level during menopause is associated with an
185 increased expression of pro-inflammatory cytokines, incl. interleukin 6 and tumor necrosis
186 factor (TNF) α (12,14,15). A cytokine storm as an adverse immune response to a SARS-
187 CoV-2 infection is currently a major hypothesis for the underlying cause of a large proportion
188 of COVID-19 deaths (16). Sufficient 25(OH)D levels are suggested to contribute to
189 prevention of the cytokine storm (17, 18). This may be especially important in
190 postmenopausal women who tend to have both lower 25(OH)D levels and a higher
191 inflammatory burden than men.

192 Although specific data for the role of vitamin D₃ in protecting from SARS-CoV-2 infections
193 and their consequences are yet to be published it appears plausible to assume that these
194 mechanisms would be relevant for this infection in a similar manner as for other severe viral
195 respiratory diseases, such as influenza. In a meta-analysis of individual participant data of 25
196 RCTs that included 11,321 participants, aged 0–95 years, vitamin D₃ supplementation was
197 shown to reduce the risk of acute respiratory tract infection (OR 0.88, 95% CI 0.81–0.96) (2).
198 The best effects were shown for daily or weekly vitamin D₃ supplementation without
199 additional bolus doses (OR 0.81, 95% CI 0.72 to 0.91). The protective effects were
200 particularly strong in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (OR 0.30,
201 95% CI 0.17– 0.53), suggesting an approximately 3-fold risk among people with vitamin D
202 deficiency not receiving vitamin D₃ supplementation compared to people with vitamin D
203 deficiency receiving supplementation. In a recent meta-analysis of RCTs on vitamin D₃
204 supplementation for patients with COPD, the risk of acute exacerbations was estimated to be
205 reduced by 61% (95% CI 36%-77%) (19). In remarkable consistency with our results, these

206 meta-analyses of RCTs provide strong evidence for the preventive potential of vitamin D₃
207 supplementation against acute respiratory infections and COPD exacerbations in particular.

208 A first study posted on a pre-print server on May 13, 2020 suggests that the protective
209 effects of vitamin D₃ on other acute respiratory tract infections may be translated to COVID-
210 19 infections (20). Vitamin D deficiency and vitamin D₃ treatment data were available for 499
211 COVID-19 patients from Chicago for the year prior COVID-19 testing. Being likely vitamin D
212 deficient (defined as being vitamin D deficient at last available time point without increase of
213 vitamin D treatment) at the time of COVID-19 testing was associated with a 1.8-fold
214 increased risk of being tested positive for COVID-19 ($p < 0.02$) as compared to likely vitamin D
215 sufficient.

216 It is worth noting that beneficial effects of vitamin D₃ supplementation against manifestation
217 or exacerbation of acute respiratory infection during an epidemic would be expected to go
218 beyond individual protection of those using supplementation, as limiting such manifestation
219 and exacerbation would also be expected to reduce the potential of spread of the disease to
220 other persons and relieve the overload of the medical system by the epidemic.

221 To our knowledge, no previous vitamin D₃ supplementation RCTs have addressed mortality
222 from respiratory disease as primary endpoint, and no meta-analysis of results for this specific
223 endpoint have been reported, which most likely reflects the relatively small share of deaths
224 from this endpoint among all deaths. In our cohort of older adults these deaths accounted for
225 5.2% of all deaths. Even though this proportion is expected to be higher during the COVID-
226 19 pandemic, the majority of deaths still occur from other diseases, and the summary effect,
227 benefit-harm ratio and cost-effectiveness with respect to all relevant outcomes therefore
228 deserve most careful attention for any general prevention efforts.

229 In that respect, vitamin D₃ supplementation appears to be a particularly promising approach,
230 especially for population groups with high prevalence of vitamin D insufficiency or deficiency,
231 such as the elderly and those with severe comorbidities (which essentially coincide with
232 population groups at highest risk of severe course and death from SARS-CoV-2 infection

233 (21)): The personal, health care and societal costs of the vitamin D₃ intervention are
234 negligibly low compared to the very high costs of currently employed “general population
235 measures”, such as extensive testing for the infection and the lockdown of large proportions
236 of economic and social life, including the delay or omission of much of routine medical care
237 for other relevant diseases. In fact, some of these measures are expected to severely
238 aggravate vitamin D insufficiency or deficiency, especially in high risk groups, such as
239 restrictions of spending time outdoors for the total population (as practiced, for example, in
240 France and Spain) or certain high risk groups, such as nursing home residents (as practiced
241 in many countries including Germany). Such restrictions dramatically reduce opportunities to
242 maintain adequate vitamin D levels through endogenous synthesis by relevant sun exposure.

243 Vitamin D₃ supplementation has been demonstrated to be safe in numerous large scale
244 studies, and the risk of harm seems to be negligible compared to the risk of harmful side
245 effects of the aforementioned and other general population measures, such as delayed
246 diagnosis and treatment of cancer, myocardial infarction or stroke, withheld or deferred
247 delivery of surgical or other medical services, or health risks related to unemployment and
248 loneliness (22-25). On the contrary, one expected “side effect” would be reducing total
249 cancer mortality by 13%, as suggested by a recent meta-analysis of RCTs (3). For Germany,
250 with currently approximately 230,000 deaths from cancer per year (26), this would translate
251 in prevention of approximately 30,000 cancer deaths each year, suggesting substantial
252 additional benefit besides lowering the COVID-19 burden during the COVID-19 pandemic
253 and beyond.

254 In conclusion, our results, along with evidence from meta-analyses from RCTs regarding
255 results of vitamin D₃ supplementation on various outcomes, suggest that vitamin D₃
256 supplementation could make a major contribution to lowering mortality from respiratory and
257 other diseases during and beyond the COVID-19 pandemic, in particular among women. The
258 Endocrine Society recommends 1,500-2,000 IU vitamin D₃/day for adults of any age at high
259 risk for vitamin D deficiency (27). The costs for such supplementation are in the order of 30 €

260 per person per year, or even half that amount when sufficient vitamin D supply is ensured by
261 carefully dosed sun exposure during the summer months. Along with expected savings from
262 prevented respiratory and other diseases, this would make vitamin D₃ supplementation a
263 particularly cost-effective and most likely cost-saving measure, whose currently still widely
264 neglected potential should receive increased attention and should more widely be utilized in
265 the fight against the COVID-19 pandemic and beyond.

266

267 **Acknowledgements**

268 The ESTHER study was funded by grants from the Saarland state Ministry for Social Affairs,
269 Health, Women and Family Affairs (Saarbrücken, Germany), the Baden-Württemberg state
270 Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education
271 and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens,
272 Women and Youth (Berlin, Germany). The authors have no conflicts of interest to disclose.
273 The author contributions were as follows: HB designed the research and drafted the
274 manuscript, BS conducted statistical analyses, and BH critically read and commented the
275 manuscript and added aspects to the discussion. All authors contributed to the data collection
276 for this project.

277

278

References

- 279 1. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence
280 that vitamin D supplementation could reduce risk of influenza and COVID-19 infections
281 and deaths. *Nutrients* 2020;12(4).
- 282 2. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin
283 D supplementation to prevent acute respiratory tract infections: systematic review and
284 meta-analysis of individual participant data. *BMJ* 2017;356:i6583
- 285 3. Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D Supplements
286 and Total Cancer Incidence and Mortality: a Meta-analysis of randomized controlled
287 trials. *Ann Oncol* 2019;30(5):733-43.
- 288 4. Schöttker B, Haug U, Schomburg L, Köhrle J, Perna L, Müller H, et al. Strong
289 associations of 25-hydroxyvitamin D levels with all-cause, cardiovascular, cancer and
290 respiratory disease mortality in a large cohort study. *Am J Clin Nutr* 2013;97:782-93.
- 291 5. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot Ld, et al; Consortium on
292 Health and Ageing: Network of Cohorts in Europe and the United States. Vitamin D and
293 mortality: meta-analysis of individual participant data from a large consortium of cohort
294 studies from Europe and the United States. *BMJ* 2014;348:g3656
- 295 6. Schöttker B, Brenner H. Vitamin D as a resilience factor, helpful for survival of potentially
296 fatal conditions: a hypothesis emerging from recent findings of the ESTHER cohort study
297 and the CHANCES consortium. *Nutrients* 2015;7(5):3264-78.
- 298 7. Brenner H, Jansen L, Saum KU, Holleczeck B, Schöttker B. Vitamin D supplementation
299 trials aimed at reducing mortality have much higher power when focusing on people with
300 low serum 25-hydroxyvitamin D concentrations. *J Nutr.* 2017;147(7):1325-1333.
- 301 8. Schöttker B, Hagen L, Zhang Y, Gào X, Holleczeck B, Gao X, et al. Serum 25-
302 hydroxyvitamin D levels as an aging marker: strong associations with age and all-cause
303 mortality independent from telomere length, epigenetic age acceleration, and 8-
304 isoprostane levels. *J Gerontol A Biol Sci Med Sci.* 2019;74(1):121-128.
- 305 9. Löw M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H. [Epidemiological
306 investigations of the chances of preventing, recognizing early and optimally treating
307 chronic diseases in an elderly population (ESTHER study)]. *Dtsch Med Wochenschr*
308 2004;129:2643-7.
- 309 10. Slomski A. IOM endorses vitamin D, calcium only for bone health, dispels deficiency
310 claims. *JAMA* 2011;305:453-4, 456.
- 311 11. World Health Organization health statistics and information systems. Metrics: Population
312 attributable fraction (PAF).
313 https://www.who.int/healthinfo/global_burden_disease/metrics_paf/en/. Accessed May 2,
314 2020.
- 315 12. Gubbels Bupp MR, Potluri T, Fink AL, et al. The Confluence of Sex Hormones and Aging
316 on Immunity. *Front Immunol* 2018; 9: 1269.
- 317 13. Yang Y, Kozloski M. Sex differences in age trajectories of physiological dysregulation:
318 inflammation, metabolic syndrome, and allostatic load. *J Gerontol A Biol Sci Med Sci*
319 2011;66:493–500.
- 320 14. Straub RH. The complex role of estrogens in inflammation. *Endocr Rev* 2007; 28(5):
321 521–74
- 322 15. Wang Y, Mishra A, Brinton RD. Transitions in metabolic and immune systems from pre-
323 menopause to post-menopause: implications for age-associated neurodegenerative
324 diseases. *F1000Res.* 2020;9:F1000 Faculty Rev-68. Published 2020 Jan 30.
325 doi:10.12688/f1000research.21599.1

- 326 16. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism
327 of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-
328 aging". *Inflamm Res*. 2020 Jun 11:1–15. doi: 10.1007/s00011-020-01372-8. Epub ahead
329 of print.
- 330 17. Daneshkhah A, Agrawal V, Eshein A, Subramanian H, Kumar Roy H, Backman V. The
331 Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in
332 COVID-19 Patients. *medRxiv* 2020.04.08.20058578; doi:
333 <https://doi.org/10.1101/2020.04.08.20058578>.
- 334 18. Quesada-Gomez JM, Castillo ME, Bouillon R. Vitamin D Receptor stimulation to reduce
335 Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2
336 infections. *J Steroid Biochem Mol Biol* 2020 Jun 11:105719. doi:
337 [10.1016/j.jsbmb.2020.105719](https://doi.org/10.1016/j.jsbmb.2020.105719). Epub ahead of print.
- 338 19. Li X, He J, Yu M, Sun J. The efficacy of vitamin D therapy for patients with COPD: a
339 meta-analysis of randomized controlled trials. *Ann Palliat Med* 2020;9(2):286-97.
- 340 20. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D
341 Deficiency and Treatment with COVID-19 Incidence *medRxiv* 2020.05.08.20095893; doi:
342 <https://doi.org/10.1101/2020.05.08.20095893>.
- 343 21. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A
344 systematic literature review and meta-analysis. *J Infect* 2020; [Epub ahead of print].
345 doi:10.1016/j.jinf.2020.04.021
- 346 22. Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary
347 syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response
348 causes cardiac collateral damage. *Eur Heart J* 2020 Apr 16. [Epub ahead of print].
- 349 23. Tapper EB, Asrani SK. COVID-19 pandemic will have a long-lasting impact on the quality
350 of cirrhosis care. *J Hepatol* 2020 Apr 13. [Epub ahead of print].
- 351 24. Baddour K, Kudrick LD, Neopaney A, Sabik LM, Peddada SD, Nilsen ML, et al. Potential
352 impact of the COVID-19 pandemic on financial toxicity in cancer survivors. *Head Neck*.
353 2020 Apr 24. [Epub ahead of print].
- 354 25. Søreide K, Hallet J, Matthews JB, Schnitzbauer AA, Line PD, Lai PBS, et al. Immediate
355 and long-term impact of the COVID-19 pandemic on delivery of surgical services. *Br J*
356 *Surg* 2020 Apr 30. [Epub ahead of print].
- 357 26. Zentrum für Krebsregisterdaten (ZfKD) im Robert Koch-Institut, Gesellschaft der
358 epidemiologischen Krebsregister e.V. (GEKID) (Eds.). *Krebs in Deutschland für*
359 *2015/2016*. Berlin, Robert Koch-Institut, 2019.
- 360 27. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention
361 of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol*
362 *Metab* 2011;96(7):1911-30.

Table 1 – Distribution of characteristics of the study population, and prevalence of vitamin D deficiency and insufficiency by those characteristics

Characteristic	Proportion of characteristic in total population [%]	Prevalence of vitamin D insufficiency among subjects with characteristic [%]	Prevalence of vitamin D deficiency among subjects with characteristic [%]	p
Total cohort	100.0	43.8	15.1	
Sex				<0.0001
Female	56.2	52.6	15.7	
Male	43.8	32.6	14.2	
Age (years)				<0.0001
50-64	61.3	42.4	14.2	
65-69	22.9	45.2	15.5	
70-75	15.8	47.3	17.7	
Month of recruitment (Season)				<0.0001
Jan-Feb	21.7	45.7	24.4	
Mar-Apr	13.9	51.6	21.2	
Mai-Jun	14.2	47.8	12.4	
Jul-Aug	17.0	35.6	6.9	
Sep-Oct	17.0	37.0	8.1	
Nov-Dec	16.2	47.0	15.6	
School education				<0.0001
≤ 9 years	75.0	44.7	15.3	
9 – 11 years	14.1	44.3	13.5	
≥ 12 years	11.0	36.1	15.4	
Smoking				<0.0001
Never	50.5	47.9	14.5	
Former	32.6	37.6	12.2	
Current	16.9	43.2	21.4	
BMI (kg/m ²)				<0.0001
< 30	74.5	42.1	14.1	
≥ 30	25.5	48.9	17.9	
Physical activity ^a				<0.0001
Low	67.1	45.9	16.7	
Moderate or high	32.9	39.6	11.6	
Fish consumption at least once per week				0.027
No	33.5	44.6	15.6	
Yes	66.5	43.2	14.2	

Abbreviations: BMI, body mass index

^a Defined by ≤ 1 h/week of vigorous physical activity that causes sweating

Table 2. Mortality from major causes of death among people with vitamin D deficiency and insufficiency compared to people with sufficient vitamin D status.

Cause of death	25(OH)D [nmol/L]	Participants	Number of deaths	Mortality ^a	Age, sex and season adjusted model		Full model	
					Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI) ^b	p-value
Any cause	> 50	3924	873	15.6	Ref		Ref	
	30-50	4186	1010	17.1	1.28 (1.16-1.41)	<0.0001	1.20 (1.09-1.32)	0.0002
	< 30	1438	480	24.9	1.91 (1.70-2.15)	<0.0001	1.67 (1.48-1.89)	<0.0001
Cardiovascular disease	> 50	3924	313	5.6	Ref		Ref	
	30-50	4186	344	5.8	1.18 (1.00-1.39)	0.0452	1.10 (0.94-1.30)	0.2329
	< 30	1438	158	8.2	1.73 (1.41-2.12)	<0.0001	1.52 (1.23-1.86)	<0.0001
Cancer	> 50	3924	328	5.9	Ref		Ref	
	30-50	4186	344	5.8	1.17 (1.00-1.38)	0.0491	1.10 (0.94-1.29)	0.2320
	< 30	1438	153	7.9	1.58 (1.28-1.92)	<0.0001	1.38 (1.13-1.70)	0.0020
Respiratory disease ^c	> 50	3924	34	0.6	Ref		Ref	
	30-50	4186	58	1.0	2.24 (1.45-3.52)	0.0004	2.06 (1.32-3.21)	0.0015
	< 30	1438	31	1.6	3.69 (2.18-6.21)	<0.0001	3.04 (1.79-5.17)	<0.0001

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; Ref, reference

^a Mortality rate per 1000 person-years.

^b Estimate from Cox proportional hazards regression model adjusted for sex, age, season of blood draw, school education, smoking, body mass index, physical activity, and fish consumption.

° Allocated to the following ICD-10-code groups: n=11, J18 - pneumonia; n=2, J41-J42 - chronic bronchitis; n=3, J43 - emphysema; n=75, J44 - COPD; n=2, J45 - asthma; n=12, J60-J70 - Lung diseases due to external agents; n=14, J80-J84 - Other respiratory diseases principally affecting the interstitium; n=1, J90-J94 Other diseases of pleura; n=2, J95-J99 - Other diseases of the respiratory system.

Table 3. Sex specific analysis on the associations of vitamin D deficiency and insufficiency with mortality from major causes of death.

Cause of death	25(OH)D [nmol/L]	Women					Men					p-value for interaction
		N _{total}	N _{deaths}	Mortality ^a	Hazard ratio (95% CI) ^b	p-value	N _{total}	N _{deaths}	Mortality ^a	Hazard ratio (95% CI) ^b	p-value	
Any cause	> 50	1701	235	9.4	Ref		2223	638	20.8	Ref		
	30-50	2821	558	13.7	1.24 (1.06-1.45)	0.0070	1365	452	24.7	1.19 (1.05-1.35)	0.0071	0.713
	< 30	843	246	21.0	1.76 (1.45-2.12)	<0.0001	595	234	30.8	1.66 (1.42-1.96)	<0.0001	0.703
Cardiovascular disease	> 50	1701	81	3.2	Ref		2223	232	7.5	Ref		
	30-50	2821	190	4.7	1.17 (0.90-1.53)	0.245	1365	154	8.4	1.11 (0.90-1.38)	0.3159	0.770
	< 30	843	90	7.7	1.78 (1.30-2.44)	0.0003	595	68	9.0	1.37 (1.02-1.83)	0.0335	0.198
Cancer	> 50	1701	95	3.8	Ref		2223	233	7.6	Ref		
	30-50	2821	188	4.6	1.12 (0.87-1.44)	0.3922	1365	156	8.5	1.09 (0.88-1.34)	0.4262	0.770
	< 30	843	64	5.5	1.22 (0.87-1.70)	0.2450	595	89	11.7	1.58 (1.22-2.07)	0.0007	0.198
Respiratory disease	> 50	1701	3	0.1	Ref		2223	31	1.0	Ref		
	30-50	2821	23	0.6	4.28 (1.27-1.42)	0.0189	1365	35	1.9	1.89 (1.14-3.15)	0.0136	0.201
	< 30	843	16	1.4	8.47 (2.38-30.12)	0.0010	595	15	2.0	2.25 (1.14-4.42)	0.0190	0.041

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; Ref, reference

^a Mortality rate per 1000 person-years.

^b Estimate from Cox proportional hazards regression model adjusted for sex, age, season of blood draw, school education, smoking, body mass index, physical activity, and fish consumption.




Figure 1. Prevalence of vitamin D deficiency and insufficiency (A) and proportion of deaths from respiratory diseases statistically attributable to these conditions (B)